PPMI Publications

Publication of PPMI data is a major goal of the PPMI Steering Committee, the Industry Scientific Advisory Board, and the study sponsor, The Michael J. Fox Foundation for Parkinson’s Research. Select publications will be posted to the website. There are three categories of PPMI publications as defined below:

  • Primary Publications: Authored by the Steering Committee, Investigators, Study Cores and Working Groups, reflecting the contribution of those authors. Primary Publications are defined as those reports, analyses, and publications identified by the PPMI SC as fulfilling the primary objectives of the study as stated in the PPMI protocol. Examples of these reports include publications detailing the baseline and longitudinal PPMI data and publications establishing and/or comparing clinical/imaging/biologic markers of Parkinson’s disease (PD) progression. “And The Parkinson’s Progression Markers Initiative*” will be written on the author line of the manuscript with an asterisk referring to the list of names of individuals identified on the PPMI Author List. The author list must be include as an appendix to ensure that all authors may be cited. All Primary Publications must collaborate with the PPMI Statistics Core and must be sent to both the PPMI Steering Committee and the PPMI DPC for review prior to journal submission. To submit to the SC, email ppmi@michaeljfox.org; to submit to the DPC, please upload the publication for review via the PPMI website.
  • Member-Initiated Publications: Authored by members of the Steering Committee, Investigators, Study Cores, and Working Groups. These publications do not meet the criteria to be Primary Publications and need not use the PPMI Statistics Core for their analysis. Examples include sub-group analyses and analyses of ancillary biomarkers. Authors must share the aims of the analysis early with the ESC, share the analysis with the PPMI Statistics Core prior to submission, and submit analytical datasets/statistical code to LONI as needed. As with Primary Publications, the phrase, “And The Parkinson’s Progression Markers Initiative*” should be included at the end of the named authors with an asterisk referring to the PPMI author list, which must be included as an appendix to ensure that all authors may be cited.
  • All Other Publications Utilizing PPMI Data: It is expected that investigators outside of the study will conduct research and seek to publish analyses using PPMI data and specimens. These individuals are encouraged to publish novel scientific findings that result from their research using PPMI. Authorship of such a publication will not include PPMI in the author line, but will acknowledge PPMI personnel and PPMI funding support as detailed in the PPMI Publications Policy and must be sent to the PPMI DPC for administrative review prior to journal submission.

Free Public Access to PPMI Publications

The intent of the PPMI publication policy is to provide for open, free, public access to analyses of PPMI data. Publications authored by the Steering Committee or by PPMI investigators using PPMI data shall be published in an open-access journal or in a hybrid open access journal as a fully open access article, and/or posted to an open-access repository under the Creative Commons Attribution 4.0 Generic License (CC BY 4.0) or an equivalent license. BioRxiv (“Bio-Archive”: http://www.biorxiv.org/) is the preferred repository for PPMI publications. Publication under other, more restrictive licenses (e.g. CC-BY-SA) may be considered on a case-by-case basis. Under extraordinary circumstances, authors may request an exception to this policy by applying to the PPMI Executive Steering Committee. Authors may submit requests to PPMI’s sponsor, MJFF, to cover the fees required by a publisher to effect publication on the aforementioned terms. Requests for cost coverage of publication fees must be made prior to the author paying fees to the publisher. Requests for retroactive reimbursement for open access fees may be considered by MJFF on a case-by-case basis. External users of PPMI data are strongly encouraged to publish results in open-access journals or in a hybrid open access journal as a fully open access article, and/or post to open repositories.

Displaying 191 publication(s).


Primary PPMI Publications

Title Author(s) Citation Keyword(s) PMID
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. Irwin DJ, Fedler J, Coffey CS, Caspell-Garcia C, Kang JH, Simuni T, Foroud T, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Weintraub D, Mollenhauer B, Galasko DR, Siderowf A, Marek K, Trojanowski JQ, Shaw LM; Parkinson\'s Progression Marker Initiative Ann Neurol. 2020 Jun 16 32542885
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Simuni T1, Uribe L2, Cho HR2, Caspell-Garcia C2, Coffey CS2, Siderowf A3, Trojanowski JQ4, Shaw LM4, Seibyl J5, Singleton A6, Toga AW7, Galasko D8, Foroud T9, Tosun D10, Poston K11, Weintraub D12, Mollenhauer B13, Tanner CM10, Kieburtz K14, Chahine LM15, Reimer A16, Hutten SJ16, Bressman S17, Marek K5; PPMI Investigators. MDSJan2020 31678032
Dopamine transporter imaging predicts clinically-de?ned ?-synucleinopathy in REM sleep behavior disorder Lana M. Chahine1 , Michael C. Brumm2, Chelsea Caspell-Garcia2, Wolfgang Oertel3, Brit Mollenhauer4,5, Amy Amara6, Ana Fernandez-Arcos7, Eduardo Tolosa7, Cristina Simonet7, Birgit Hogl8, Aleksandar Videnovic9, Samantha J. Hutten10, Caroline Tanner11, Daniel Weintraub12, Elliot Burghardt2, Christopher Coffey2, Hyunkeun R. Cho2, Karl Kieburtz13, Kathleen L. Poston14, Kalpana Merchant15, Douglas Galasko16, Tatiana Foroud17, Andrew Siderowf18, Kenneth Marek19, Tanya Simuni15 & Alex Iranzo7
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Weintraub D, Caspell-Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M; Parkinson’s Progression Markers Initiative Ann Clin Transl Neurol. 2020 Apr;7(4):449-461 32285645
Longitudinal analyses of cerebrospinal fluid ?-Synuclein in prodromal and early Parkinson's disease. Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Singleton A; Shaw LM; Trojanowski JQ; Frasier M; Simuni T; Iranzo A; Oertel W; Siderowf A; Weintraub D; Seibyl J; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Marek K; Galasko D; PPMI study; Mov. Disord. 2019 Sep;34(9):1354-1364 31361367
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Prakash N; Caspell-Garcia C; Coffey C; Siderowf A; Tanner CM; Kieburtz K; Mollenhauer B; Galasko D; Merchant K; Foroud T; Chahine LM; Weintraub D; Casaceli C; Dorsey R; Wilson R; Herzog M; Daegele N; Arnedo V; Frasier M; Sherer T; Marek K; Simuni T; Parkinson\'s Progression Markers InitiativeSteering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board; Parkinsonism Relat. Disord. 2019 Jan;(): 30738748
Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort. Simuni T; Siderowf A; Lasch S; Coffey CS; Caspell-Garcia C; Jennings D; Tanner CM; Trojanowski JQ; Shaw LM; Seibyl J; Schuff N; Singleton A; Kieburtz K; Toga AW; Mollenhauer B; Galasko D; Chahine LM; Weintraub D; Foroud T; Tosun D; Poston K; Arnedo V; Frasier M; Sherer T; Chowdhury S; Marek K; Parkinson\'s Progression Marker Initiative*; Mov Disord. 2018 May;33(5):771-782 Parkinson's disease; disease subtypes; gait disorder predominant; postural instability; tremor dominant 29572948
Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. Amara AW; Chahine LM; Caspell-Garcia C; Long JD; Coffey C; Högl B; Videnovic A; Iranzo A; Mayer G; Foldvary-Schaefer N; Postuma R; Oertel W; Lasch S; Marek K; Simuni T; Parkinson?s Progression Markers Initiative; J. Neurol. Neurosurg. Psychiatr. 2017 Aug;88(8):653-662 Biomarkers; Excessive daytime sleepiness; Non-motor symptoms; Parkinson’s disease; Sleep 28554959
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson?s Progression Marker Initiative Acta Neuropathol. 2016 Jun;131(6):935-49. Alpha-synuclein; A1-42; Cerebrospinal fluid biomarker; Parkinson?s Progression Markers Initiative; Parkinson?s disease; Tau 27021906
How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K; PPMI Investigators. 2016 Apr 23. pii: S1353-8020(16)30131-6. doi: 10.1016/j.parkreldis.2016.04.027. [Epub ahead of print] Disease subtypes; Gait disorder predominant; Parkinson's disease; Postural instability; Tremor dominant 27132498
Predictors of Time to Initiation of Symptomatic Therapy in Early Parkinson's Disease Tanya Simuni, Jeff Long, Chelsea Caspell-Garcia, Christopher Coffey, and Ken Marek on behalf of the PPMI Investigators Ann Clin Transl Neurol. 2016 May 17;3(7):482-94 Biomarkers, Symptomatic Therapy 27386498
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Weintraub D; Simuni T; Caspell-Garcia C; Coffey C; Lasch S; Siderowf A; Aarsland D; Barone P; Burn D; Chahine LM; Eberling J; Espay AJ; Foster ED; Leverenz JB; Litvan I; Richard I; Troyer MD; Hawkins KA; and the Parkinson\'s Progression Markers Initiative Mov Disord. 2015 Jun;30(7):919-27 anxiety; apathy; cognition; depression; impulse control disorder; psychosis 25737166
Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study Simuni, T; Caspell-Garcia, C; Coffey, C; Chahine, L; Lasch, S; Oertel, W; Mayer, G; Högl, B; Postuma, R; Videnovic, A; Amara, AW; Marek, K; and for the PPMI Sleep Working group on behalf of the PPMI Investigators Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26248. [Epub ahead of print] daytime somnolence; biomarkers; daytime sleepiness; nonmotor symptoms; sleep 26095202
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, Mendick S, Seibyl J, Simuni T, Zhang Y, Jankovic J, Hunter C, Tanner CM, Rees L, Factor S, Berg D, Wurster I, Gauss K, Sprenger F, Seppi K, Poewe W, Mollenhauer B, Knake S, Mari Z, McCoy A, Ranola M, Marek K. Movement Disorders. 2015 Dec; 14(10):1002-9. dopamine; fractional anisotropy; neuroimaging; substantia nigra 26271532
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI) Nalls MA; Keller MF; Hernandez DG; Chen L; Stone DJ; Singleton AB; Parkinson\'s Progression Marker Initiative (PPMI) investigators; Mov Disord. 2016 Jan;31(1):79-85. GWAS; Parkinson's disease; genetic risk score; genetics 26268663
Novel Recruitment Strategy to Enrich for LRRK2 Mutation Carriers Tatiana Foroud, Ph.D.1, Danielle Smith, B.S.1, Jacqueline Jackson, B.S.1, Jennifer Verbrugge, M.S.1, Cheryl Halter,M.S.1, Katherine Sims, M.D.2, Winnie Xin, Ph.D.2, Vanessa Arnedo, M.P.H. 3, Shirley Lasch, B.S., M.B.A., 4, Ken Marek, M.D.4 and the Parkinson\'s Progression Markers Initiative Mol Genet Genomic Med. 2015 Sep;3(5):404-12. LRRK2, recruitment 26436106
Association of Cerebrospinal Fluid B-Amyloid 1-42, T-tau, P-tau181, and a-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM; and the Parkinson?s Progression Markers Initiative. JAMA Neurol. 2013 Oct;70(10):1277-87. alpha-synuclein; amyloid beta; tau; cerebrospinal fluid; CSF; phenotype 23979011
Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Weintraub D; Papay K; Siderowf A; Parkinson\'s Progression Markers Initiative Neurology 2013 Jan;80(2):176-80. impulse control; de novo; Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease; QUIP 23296128
The Parkinson Progression Marker Initiative (PPMI). Parkinson Progression Marker Initiative Prog. Neurobiol. 2011 Dec;95(4):629-35. biomarker; dopamine transporter imaging; diffusion tensor imaging; cerebrospinal fluid; alpha synuclein 21930184
Multiple Modality Biomarker Prediction of Cognitive Impairment in Prospectively Followed de novo Parkinson Disease Chelsea Caspell-Garcia, Tanya Simuni, Norbert Schuff, Duygu Toson-Turgut, I-Wei Wu, Yu Zhang, Mike Nalls, Andrew Singleton, Leslie A. Shaw, Ju-Hee Kang, John Q. Trojanowski, Andrew Siderowf, Christopher Coffey, Shirley Lasch, Dag Aarsland, David Burn, Lama M. Chahine, Jamie Eberling, Alberto J. Espay, Eric D. Foster, Keith A. Hawkins, Irene Litvan, Irene Richard, Daniel Weintraub, and the Parkinson\'s Progression Markers Initiative PLoS One. 2017 May 17;12(5):e0175674. 28520803


Publications Using PPMI Data

Title Author(s) Citation Keyword(s) PMID
Improving in vivo human cerebral cortical surface reconstruction using data-driven super-resolution Qiyuan Tian, Berkin Bilgic, Qiuyun Fan, Chanon Ngamsombat, Natalia Zaretskaya, Nina E. Fultz, Ned A. Ohringer, Akshay S. Chaudhari, Yuxin Hu, Thomas Witzel, Kawin Setsompop, Jonathan R. Polimeni, Susie Y. Huang 2020 September
State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson’s disease Cecilia Quarracino, Matilde Otero-Losada, Francisco Capani & Santiago Pérez-Lloret EOP. 2020 Sept
E?ect of polygenic load on striatal dopaminergic deterioration in Parkinson disease Myung Jun Lee, MD, Kyoungjune Pak, MD,Jong Hun Kim, MD, Yun Joong Kim, MD, Jeehee Yoon, PhD, Jinwoo Lee, MS, Chul Hyoung Lyoo, MD, Hyung Jun Park, MD, Jae-Hyeok Lee, MD, and Na-Yeon Jung, MD Neurology. 2020 Oct 27
Genome?Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease Tan, M.M., Lawton, M.A., Jabbari, E., Reynolds, R.H., Iwaki, H., Blauwendraat, C., Kanavou, S., Pollard, M.I., Hubbard, L., Malek, N., Grosset, K.A., Marrinan, S.L., Bajaj, N., Barker, R.A., Burn, D.J., Bresner, C., Foltynie, T., Wood, N.W., Williams?Gray, C.H., Hardy, J., Nalls, M.A., Singleton, A.B., Williams, N.M., Ben?Shlomo, Y., Hu, M.T., Grosset, D.G., Shoai, M. and Morris, H.R. (2020), Genome?Wide Association Studies of Cognitive and Motor Progression in Parkinson\'s Disease. Mov Disord. https://doi.org/10.1002/mds.28342
Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease. Craig CE; Jenkinson NJ; Brittain JS; Grothe MJ; Rochester L; Silverdale M; Alho ATDL; Alho EJL; Holmes PS; Ray NJ; Mov. Disord. 2020 May;(): 32400071
Excessive daytime sleepiness and dysphagia in Parkinson's disease, from the assessment of a risk to a pathophysiological landscape. Motolese F; Gupta D; Marano M; J. Neurol. Sci. 2020 May;():116882 32417041
Non-motor Clinical and Biomarker Predictors Enable High Cross-Validated Accuracy Detection of Early PD but Lesser Cross-Validated Accuracy Detection of Scans Without Evidence of Dopaminergic Deficit Charles Leger, Monique Herbert and Joseph F. X. DeSouza 10.3389/fneur.2020.00364
Association between hypomimia and mild cognitive impairment in de novo drug naïve Parkinson’s disease patients Carmen Gasca-Salas, Daniele Urso
Parkinson’s disease prognostic scores for progression of cognitive decline Gramotnev G, Gramotnev DK, Gramotnev A
Gastrointestinal symptoms are predictive of trajectories of cognitive functioning in de novo Parkinson's disease. Jones JD; Rahmani E; Garcia E; Jacobs JP; Parkinsonism Relat. Disord. 2020 Jan;72():7-12 32058266
Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person Chahine LM, Chin I, Caspell-Garcia C, Standaert D, Brown E, Smolensky L, Arnedo V, Daeschler D, Riley L, Korell M, Dobkin R, Amondikar N, Gradinscak S, Shoulson I, Dean M, Kwok K, Cannon P, Marek K, Kopil C, Tanner C, Marrason C; behalf of the Fox Insight Study JPD,2020, Jan 31958097
Choroid plexus volume is associated with levels of CSF proteins: relevance for Alzheimer's and Parkinson's disease. Tadayon E; Pascual-Leone A; Press D; Santarnecchi E; Alzheimer\'s Disease Neuroimaging Initiative; Neurobiol. Aging 2020 Jan;(): 32107064
Excess of singleton loss-of-function variants in Parkinson’s disease contributes to genetic risk Dheeraj Reddy Bobbili, Peter Banda, Rejko Krüger3, Patrick May 2020 Feb 13 jmedgenet-2019-106316
Constructing treatment episodes from concomitant medication logs: a prospective observational study Lisa K Kuramoto, Boris G Sobolev, Penelope M A Brasher, Michael W Tang, Jacquelyn J Cragg Kuramoto LK, Sobolev BG, Brasher PMA, et alConstructing treatment episodes from concomitant medication logs: a prospective observational studyBMJ Open 2020;10:e034305. doi: 10.1136/bmjopen-2019-034305
Longitudinal changes in autonomic symptoms predicts activities of daily living and depression in Parkinson's disease Miriam Sklerov, Chia-Hao Shih, Nina Browner, Jose-Alberto Palma, Martin Styner & Eran Dayan
Cross-sectional and longitudinal associations between probable REM sleep behavior disorder and impulse control disorders in Parkinson's disease. Cao R; Chen X; Xing F; Xie C; Hu P; Wang K; Eur. J. Neurol. 2020 Feb;(): 32065438
Beyond PD-MCI: Objectively Defined Subtle Cognitive Decline Predicts Future Cognitive and Functional Declines. Jacob Jones, Carmen Uribe, Joseph Bunch, Kelsey Thomas Jones, J.D., Uribe, C., Bunch, J. et al. Beyond PD-MCI: objectively defined subtle cognitive decline predicts future cognitive and functional changes. J Neurol (2020)
Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson’s Disease Parkinson’s Progression Markers Initiative Participants Javidnia, Monicaa; Shoulson, Iraa; Kieburtz, Karla; Venuto, Charlesa; JPD, 2020, April 10.3233/JPD-201973
Serial Dopamine Transporter Imaging of Nigrostriatal Function in Parkinson’s Disease With Probable REM Sleep Behavior Disorder Ruihua Cao, Xingui Chen, Chengjuan Xie, Panpan Hu1 and Kai Wang Front. Neurosci., 30 April 2020
Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease. Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J; Parkinsonism Relat. Disord. 2020 Apr;74():43-49 32334380
Greater Intra-Individuals Variability in Neuropsychological Performance Predicts Cognitive Impairment in De Novo Parkinson's Disease Jones, J. D., Burroughs, M., Apodaca, M., & Bunch, J Neuropsychology, 33(8), 1111–1120
Impact of the size of the normal database on the performance of the specific binding ratio in dopamine transporter SPECT Helen Schmitz-Steinkrüger, Catharina Lange, Ivayla Apostolova, Holger Amthauer, Wencke Lehnert, Susanne Klutmann, Ralph Buchert Schmitz-Steinkrüger et al. EJNMMI Physics
Development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson's disease to inform clinical trial designs. Ahamadi M; Conrado DJ; Macha S; Sinha V; Stone J; Burton J; Nicholas T; Gallagher J; Dexter D; Bani M; Boroojerdi B; Smit H; Weidemann J; Chen C; Yang M; Maciuca R; Lawson R; Burn D; Marek K; Venuto C; Stafford B; Akalu M; Stephenson D; Romero K; Critical Path for Parkinson\'s (CPP) Consortium; Clin. Pharmacol. Ther. 2019 Sep;(): 31544231
Longitudinal intracortical diffusivity changes in de-novo Parkinson's disease: A promising imaging biomarker. Sampedro F; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J; Parkinsonism Relat. Disord. 2019 Oct;68():22-25 31621613
Neuropsychological Test Performances and Depression in Early-Stage De Novo Parkinson's Disease. Honsey BN; Erickson LO; Wyman-Chick KA; Arch Clin Neuropsychol 2019 Nov;(): 31732731
Diagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: harmonized multi-center research setting versus typical clinical single-camera setting. Buchert R; Lange C; Spehl TS; Apostolova I; Frings L; Jonsson C; Meyer PT; Hellwig S; EJNMMI Res 2019 May;9(1):37 31065816
CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD. Liguori C; Paoletti FP; Placidi F; Ruffini R; Sancesario GM; Eusebi P; Mercuri NB; Parnetti L; Curr Neurol Neurosci Rep 2019 Jan;19(2):3 30637520
Higher urate in LRRK2 mutation carriers resistant to Parkinson's disease. Bakshi R; Macklin EA; Logan R; Zorlu MM; Xia N; Crotty GF; Zhang E; Chen X; Ascherio A; Schwarzschild MA; Ann. Neurol. 2019 Feb;(): 30761591
Unique white matter structural connectivity in early-stage, drug-naive Parkinson disease Virendra R. Mishra, PhD, Karthik R. Sreenivasan, MS, Zhengshi Yang, MS, Xiaowei Zhuang, MS, Dietmar Cordes, PhD, Zoltan Mari, MD, Irene Litvan, MD, Hubert H. Fernandez, MD, David Eidelberg, MD, Aaron Ritter, MD, Jeffrey L. Cummings, MD, DSc, and Ryan R. Walsh, MD, PhD Neurology. 2019 Dec 27. pii: 10.1212/WNL.0000000000008867. doi: 10.1212/WNL.0000000000008867 31882528
Modeling progression of Parkinson's disease Christina X Ji Modeling progression of Parkinson's disease
Automatic Classification of Dopamine Transporter SPECT: Deep Convolutional Neural Networks Can Be Trained to Be Robust With Respect to Variable Image Characteristics Markus Wenzel, Fausto Milletari, Julia Krüger, Catharina Lange, Michael Schenk, Ivayla Apostolova, Susanne Klutmann, Marcus Ehrenburg, Ralph Buchert Epub 2019 Aug 31 31473800
Influence of analytic techniques on comparing DTI-derived measurements in early stage Parkinson's disease. Mishra VR; Sreenivasan KR; Zhuang X; Yang Z; Cordes D; Walsh RR; Heliyon 2019 Apr;5(4):e01481 31008407
Depressive Symptoms Precede Cognitive Impairment in De Novo Parkinson's Disease Patients: Analysis of the PPMI Cohort. Jacob D. Jones, Natalie E. Kurniadi, Taylor P. Kuhn, Sarah M. Szymkowicz Joseph Bunch Neuropsychology, 33(8), 1111–1120
Early Parkinson's Disease detection using SPECT and biological biomarker Pahuja, G., Nagabhushan, T.N., and Prasad, B ournal of Intelligent Systems, Vol. 29, No. 1, pp.1329-1344 SPECT, biological, biomarker, Early Parkinson's
White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients. Dadar M; Zeighami Y; Yau Y; Fereshtehnejad SM; Maranzano J; Postuma RB; Dagher A; Collins DL; Neuroimage Clin 2018 Sep;20():892-900 Parkinson's disease, White matter hyperintensities, Magnetic resonance imaging, Cognitive decline, De novo patients 30292088
Early detection of Parkinson's disease through patient questionnaire and predictive modelling. Prashanth R, Dutta Roy S. Int J Med Inform. 2018 Nov;119:75-87. doi: 10.1016/j.ijmedinf.2018.09.008. Epub 2018 Sep 9. Computer-aided early detection; Machine learning; Parkinson's Disease (PD); Patient questionnaire (PQ); Predictive modelling 30342689
Dopaminergic degeneration induces early posterior cortical thinning in Parkinson's disease. Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J; Neurobiol. Dis. 2018 Nov;124():29-35 30408592
Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study. Delgado-Alvarado M; Dacosta-Aguayo R; Navalpotro-Gómez I; Gago B; Gorostidi A; Jiménez-Urbieta H; Quiroga-Varela A; Ruiz-Martínez J; Bergareche A; Rodríguez-Oroz MC; Mov. Disord. 2018 Nov;33(11):1809-1813 30423201
Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease Jonathan Schulz, Gennaro Pagano, Juan Alberto, Fernández Bonfante, Heather Wilson, Marios Politis Brain. 2018 May; 141(5): 1501-1516. nucleus, basalis of Meynert, MRI, DTI, cognitive decline, Parkinson’s disease 29701787
Serotonin, ?-amyloid, and cognition in Parkinson disease. Kotagal V, Spino C, Bohnen NI, Koeppe R, Albin RL. Ann Neurol. 2018 May;83(5):994-1002. doi: 10.1002/ana.25236. Epub 2018 May 11. 29665066
Symptoms and medications change patterns for Parkinson's disease patients stratification Anita Valmarska, Dragana Mijiovic, Spiros Konitsiotus, Dimitris Gatsios, Nada Lavrac, Marko Robnik-Sikonja. Parkinson's disease, Analysis of disease progression, Multitask learning, Analysis of medications treatment, Symptoms impact
Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease. Barrett MJ, Blair JC, Sperling SA, Smolkin ME, Druzgal TJ. Neurology. 2018 May 1;90(18):e1618-e1626. doi: 10.1212/WNL.0000000000005421. Epub 2018 Apr 4. 29618627
Early Gray Matter Volume Loss in MAPT H1H1 de Novo PD Patients: A Possible Association With Cognitive Decline Frederic Sampedro, Juan Marín-Lahoz, Saul Martínez-Horta, Javier Pagonabarraga, and Jaime Kulisevsky Front Neurol. 2018; 9: 394. MAPT, T1-MRI, cognitive decline, Parkinson's disease, gray matter volume 29899731
Office-Based Screening for Dementia in Parkinson Disease: The Montreal Parkinson Risk of Dementia Scale in 4 Longitudinal Cohorts. Dawson BK; Fereshtehnejad SM; Anang JBM; Nomura T; Rios-Romenets S; Nakashima K; Gagnon JF; Postuma RB; JAMA Neurol 2018 Mar;(): 29582054
Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease. Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R; Mov. Disord. 2018 Mar;33(3):431-439 29436735
Cognitive Profiles and Hub Vulnerability in Parkinson's Disease Sue-Jin Lin, Tobias R. Baumeister, Saurabh Garg, Martin J. McKeown Front. Neurol. 2018 June;8:482. 29973913
Extraction, selection and comparison of features for an effective automated computer-aided diagnosis of Parkinson's disease based on [123I]FP-CIT SPECT images Oliveira FPM, Faria DB Costa DC, Castelo-Branco M, Tavares JMRS Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1052-1062 Classification; DaTSCAN™; Dimensional-based features; PPMI database; Uptake ratios 29275487
Pallidal dopaminergic denervation and rest tremor in early Parkinson's disease: PPMI cohort analysis Lee JY, Lao-Kaim NP, Pasquini J, Deuschl G, Pavese N, Piccini P Parkinsonism Relat Disord. 2018 Jun;51:101-104. Dopamine transporter; Globus pallidus; Parkinson's disease; Rest tremor; SPECT 29503156
Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort. Kim R, Lee J, Kim Y, Kim A, Jang M, Kim HJ, Jeon B, Kang UJ, Fahn S. Parkinsonism Relat Disord. 2018 Jun;51:49-54. doi: 10.1016/j.parkreldis.2018.02.047. Epub 2018 Feb 28. Caudate; DAT; Freezing of gait; Parkinson's disease; Putamen 29523394
Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease. Pak K, Shin HK, Kim EJ, Lee JH, Lyoo CH, Son J, Lee MJ. Parkinsonism Relat Disord. 2018 Jun;51:67-72. doi: 10.1016/j.parkreldis.2018.02.044. Epub 2018 Feb 28. (123)I-FP-CIT; Body mass index; Parkinson disease; SPECT; Weight loss 29510907
Quantitative Intensity Harmonization of Dopamine Transporter SPECT Images Using Gamma Mixture Models. Llera A, Huertas I, Mir P, Beckmann CF. Mol Imaging Biol. 2018 Jul 9. doi: 10.1007/s11307-018-1217-8. [Epub ahead of print] Dopamine transporter; Gamma distribution; Intensity normalization; Multicenter studies; PPMI; SPECT 29987621
Brain tissue pulsatility is related to clinical features of Parkinson's disease Shirzadi Z, Robertson AD, Metcalfe AW, Duff-Canning S, Marras C, Lang AE, Masellis M, MacIntosh BJ Neuroimage Clin. 2018 July PMC6079564
Determination of Imaging Biomarkers to Decipher Disease Trajectories and Differential Diagnosis of Neurodegenerative Diseases (DIsease TreND). Singh G; Samavedham L; Lim EC; Alzheimer’s Disease Neuroimaging Initiative; Parkinson Progression Marker Initiative; J. Neurosci. Methods 2018 Jul;305():105-116 29800593
Identification of a prospective early motor progression cluster of Parkinson's disease: Data from the PPMI study George D. Vavougios, Triantafyllos Doskas, Constantinos Kormas, Karen A. Krogfelt, Sotirios G. Zarogiannis, Leonidas Stefanis Journal of Neuro Sci. 2018 Jan;387:103-108. Parkinson's disease Progression Biomarkers Cluster analysis Phenotypes 29571843
Semiquantitative Analysis of Dopamine Transporter Scans in Patients With Parkinson Disease. Tinaz S, Chow C, Kuo PH, Krupinski EA, Blumenfeld H, Louis ED, Zubal G. Clin Nucl Med. 2018 Jan;43(1):e1-e7. doi: 10.1097/RLU.0000000000001885. 29112012
Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K; J. Neurol. Neurosurg. Psychiatry 2018 Jan;89(1):78-88 28986467
Reverters from PD-MCI to cognitively intact are at risk for future cognitive impairment: Analysis of the PPMI cohort. Jones JD, Kuhn TP, Szymkowicz SM. Send to Parkinsonism Relat Disord. 2018 Feb;47:3-7. doi: 10.1016/j.parkreldis.2017.12.006. Epub 2017 Dec 9. Dementia; Mild cognitive impairment; Neuropsychology; Parkinson's disease 29233608
Differential White Matter Regional Alterations in Motor Subtypes of Early Drug-Naïve Parkinson's Disease Patients. Wen MC, Heng HSE, Lu Z, Xu Z, Chan LL, Tan EK, Tan LCS. Neurorehabil Neural Repair. 2018 Feb;32(2):129-141. doi: 10.1177/1545968317753075. Epub 2018 Jan 19. Parkinson’s Progression Markers Initiative; diffusivity; fractional anisotropy; postural instability and gait difficulty; tremor; white matter 29347868
Selection of normative group affects rates of mild cognitive impairment in Parkinson's disease. Wyman-Chick KA; Martin PK; Weintraub D; Sperling SA; Erickson LO; Manning CA; Barrett MJ; Mov. Disord. 2018 Feb;(): 29442392
Microstructural changes in patients with Parkinson disease and REM sleep behavior disorder: depressive symptoms versus non-depressed. Ghazi Sherbaf F; Rahmani F; Jooyandeh SM; Aarabi MH; Acta Neurol Belg 2018 Feb;(): 29442234
Cortical atrophy patterns in early Parkinson's disease patients using hierarchical cluster analysis. Uribe C; Segura B; Baggio HC; Abos A; Garcia-Diaz AI; Campabadal A; Marti MJ; Valldeoriola F; Compta Y; Tolosa E; Junque C; Parkinsonism Relat. Disord. 2018 Feb;(): 29449187
Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease. Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M; Eur. J. Neurol. 2018 Feb;25(2):307-312 29078029
Risk variants of the ?-synuclein locus and REM sleep behavior disorder in Parkinson's disease: a genetic association study. Bjørnarå KA; Pihlstrøm L; Dietrichs E; Toft M; BMC Neurol 2018 Feb;18(1):20 29466944
Self-reported physical activity levels and clinical progression in early Parkinson's disease. Amara AW; Chahine L; Seedorff N; Caspell-Garcia CJ; Coffey C; Simuni T; Parkinson\'s Progression Markers Initiative; Parkinsonism Relat. Disord. 2018 Dec;(): 30554993
Novel and improved stage estimation in Parkinson's disease using clinical scales and machine learning R.Prashanth, Sumantra Dutta Roy Neurocomputing. 2018 Aug 305: 78-103 Parkinson's disease (PD), Computer-aided diagnosis, Medical expert systems, Predictive models, Machine learning
Physical Activity in Early Parkinson Disease Mantri S, Fullard ME, Duda JE, Morley JF J Parkinsons Dis. 2018; 8(1): 107–111. 29480222
Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease. Fischer DL, Auinger P, Goudreau JL, Paumier KL, Cole-Strauss A, Kemp CJ, Lipton JW, Sortwell CE. Parkinsonism Relat Disord. 2018 Aug;53:70-75. doi: 10.1016/j.parkreldis.2018.05.003. Epub 2018 May 9. Brain-derived neurotrophic factor; Levodopa; Single nucleotide polymorphism; Val66Met; rs6265 29759928
Modifiable Vascular Risk Factors, White Matter Disease, and Cognition in Early Parkinson's Disease. Chahine LM; Dos Santos C; Fullard M; Scordia S; Weintraub D; Erus G; Rosenthal L; Davatzikos C; McMillan CT; Eur. J. Neurol. 2018 Aug;(): 30169897
Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Hinkle JT; Perepezko K; Mills KA; Mari Z; Butala A; Dawson TM; Pantelyat A; Rosenthal LS; Pontone GM; Parkinsonism Relat. Disord. 2018 Aug;(): 30146185
Increased odds of bladder and bowel symptoms in early Parkinson's disease. Serra MC, Landry A, Juncos JL, Markland AD, Burgio KL, Goode PS, Johnson TM, Vaughan CP. Neurourol Urodyn. 2018 Apr;37(4):1344-1348. doi: 10.1002/nau.23443. Epub 2017 Nov 2. Parkinson's disease; constipation; epidemiology; fecal incontinence; urinary incontinence 29095515
Correlation between the availability of dopamine transporter and olfactory function in healthy subjects. Pak K, Kim K, Lee MJ, Lee JM, Kim BS, Kim SJ, Kim IJ. Eur Radiol. 2018 Apr;28(4):1756-1760. doi: 10.1007/s00330-017-5147-7. Epub 2017 Nov 21. Brain; Dopamine plasma membrane transport proteins; Nuclear medicine; Smell; Tomography, emission computed, single photon 29164380
A similarity-based approach to leverage multi-cohort medical data on the diagnosis and prognosis of Alzheimer's disease. Zhang H; Zhu F; Dodge HH; Higgins GA; Omenn GS; Guan Y; Alzheimer\'s Disease Neuroimaging Initiative; Gigascience 2018 07;7(7): 30010762
Robust Ensemble Classification Methodology for I123-Ioflupane SPECT Images and Multiple Heterogeneous Biomarkers in the Diagnosis of Parkinson's Disease. Castillo-Barnes D; Ramírez J; Segovia F; Martínez-Murcia FJ; Salas-Gonzalez D; Górriz JM; Front Neuroinform 2018 ;12():53 30154711
Structural Brain Network Alteration and its Correlation With Structural Impairments in Patients With Depression in and Drug-Naïve Parkinson's Disease. Gou L; Zhang W; Li C; Shi X; Zhou Z; Zhong W; Chen T; Wu X; Yang C; Guo D; Front Neurol 2018 ;9():608 30093879
Joint regression and classification via relational regularization for Parkinson’s disease diagnosis Lei H, Huang Z, Han T, Luo Q, Cai Y, Liu G, Lei B Technol Health Care. 2018;26(S1):19-30. Parkinson’s disease; classification; feature selection; multi-modality; score prediction 29689760
Sparse feature learning for multi-class Parkinson's disease classification. Lei H, Zhao Y, Wen Y, Luo Q, Cai Y, Liu G, Lei B. Technol Health Care. 2018;26(S1):193-203. Parkinson’s disease; classification; feature selection; multi-class 29710748
Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset. Fiorenzato E; Biundo R; Cecchin D; Frigo AC; Kim J; Weis L; Strafella AP; Antonini A; J. Alzheimers Dis. 2018 ;66(1):229-237 30282359
Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure. Ghazi Sherbaf F; Mohajer B; Ashraf-Ganjouei A; Mojtahed Zadeh M; Javinani A; Sanjari Moghaddam H; Shirin Shandiz M; Aarabi MH; Front Endocrinol (Lausanne) 2018 ;9():608 30450079
Cognition among individuals along a spectrum of increased risk for Parkinson's disease. Chahine LM; Urbe L; Caspell-Garcia C; Aarsland D; Alcalay R; Barone P; Burn D; Espay AJ; Hamilton JL; Hawkins KA; Lasch S; Leverenz JB; Litvan I; Richard I; Siderowf A; Coffey CS; Simuni T; Weintraub D; Parkinson’s Progression Markers Initiative; PLoS ONE 2018 ;13(8):e0201964 30125297
Regional expression of genes mediating trans-synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease. Freeze B; Acosta D; Pandya S; Zhao Y; Raj A; Neuroimage Clin 2018 ;18():456-466 29868450
Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. Iddi S; Li D; Aisen PS; Rafii MS; Litvan I; Thompson WK; Donohue MC; Neurodegener Dis 2018 ;18(4):173-190 30089306
Early detection of Parkinson’s disease through multimodal features using machine learning approaches Pahuja, G., Nagabhushan, T.N., Prasad, B. and Pushkarna, R Int. J. Signal and Imaging Systems Engineering, Vol. 11, No. 1, pp.31–43. Early detection, multimodal features, machine
A comparative study of feature projection and feature selection methods for PD detection and classification using T1 weighted Images Pahuja, G., Nagabhushan, T.N., and Prasad, B Int. J. Biomedical Engineering & Technology feature projection, feature selection, T1 weighted Images, comparative
Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson?s Disease Patients Simon Buatois, Sylvie Retout, Nicolas Frey, Sebastian Ueckert Buatois, S., Retout, S., Frey, N. et al. Pharm Res (2017) 34: 2109. https://doi.org/10.1007/s11095-017-2216-1 drug effect, item response theory, MDS-UPDRS, Parkinson?s disease, pharmacometrics 22300470
Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. Picillo M, Pivonello R, Santangelo G, Pivonello C, Savastano R, Auriemma R, Amboni M, Scannapieco S, Pierro A, Colao A, Barone P, Pellecchia MT PLoS One. 2017 Oct 24;12(10) 5655531
Predictors of anxiety in early-stage Parkinson's disease - Results from the first two years of a prospective cohort study Rutten S, van der Ven PM, Weintraub D, Pontone GM, Leentjens AFG, Berendse HW, van der Werf YD, van den Heuvel OA Parkinson Related Disord. 2017 October; 43:49-55.
Machine Learning Interface for Medical Image Analysis Zhang YC, Kagen AC J Digit Imaging. 2017 Oct;30(5):615-621. Artificial intelligence; Classification; Computer vision; Image analysis 27730415
Patterns of grey matter loss associated with motor subscores in early Parkinson's disease Li X, Xing Y, Martin-Bastida A, Piccini P, Auer DP Neuroimage Clin. 2017 Nov 10;17:498-504 MDS-UPDRS III; MRI grey matter; Motor symptoms; PD subtypes; Parkinson's disease 29201638
Comparison of machine learning and semi-quantification algorithms for (I123)FP-CIT classification: the beginning of the end for semi-quantification? Taylor JC, Fenner JW EJNMMI Phys. 2017 Nov 4(1):29 123I-FP; DaTSCAN; Machine learning; Parkinson’s disease; Semi-quantification; Support vector machine 29188397
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Shaw LM; Trojanowski JQ; Singleton A; Frasier M; Marek K; Galasko D; Parkinson\'s Progression Marker Initiative; Neurology 2017 Nov;89(19):1959-1969 29030452
Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation. Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS; Lancet Neurol 2017 Nov;16(11):908-916 28958801
Exploring the reproducibility of functional connectivity alterations in Parkinson's disease Badea L, Onu M, Wu T, Roceanu A, Bajenaru O PLOS ONE 13(5): e0197121. PMC5705108
The influence of vascular risk factors on cognitive function in early Parkinson's disease. Doiron M, Langlois M, Dupré N, Simard M. Int J Geriatr Psychiatry. 2017 May 16. doi: 10.1002/gps.4735. [Epub ahead of print] 28509343
Distinct Role of Striatal Functional Connectivity and Dopaminergic Loss in Parkinson?s Symptoms Juergen Dukart, Fabio Sambataro and Alessandro Bertolino Frontiers Aging Neurosci 2017, May. 9:151. doi: 10.3389/fnagi.2017.00151 28588475
Voxel-based Logistic Analysis of PPMI Control and Parkinson's Disease DaTscans Hemant D. Tagare, Christine DeLorenzo, Sudhakar Chelikani, Lawrence Saperstein, Robert K. Fulbright NeuroImage. 2017 May;152:299-311 Parkinson's disease; DaTscan; PPMI; Logistic Lasso; Logistic Principal Components 28254511
Diagnostic Accuracy and Confidence in the Clinical Detection of Cognitive Impairment in Early-Stage Parkinson Disease. Wyman-Chick KA; Martin PK; Barrett MJ; Manning CA; Sperling SA; J Geriatr Psychiatry Neurol 2017 May;30(3):178-183 28351200
Complex networks reveal early MRI markers of Parkinson's disease. Amoroso N, La Rocca M, Monaco A, Bellotti R, Tangaro S. Med Image Anal. 2018 Aug;48:12-24. doi: 10.1016/j.media.2018.05.004. Epub 2018 May 17. Complex networks; MRI; Machine learning; Parkinson’s disease 29807313
A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease. Hayete B, Wuest D, Laramie J, McDonagh P, Church B, Eberly S, Lang A, Marek K, Runge K, Shoulson I, Singleton A, Tanner C, Khalil I, Verma A, Ravina B. PLoS One. 2017 Jun 12;12(6):e0178982. doi: 10.1371/journal.pone.0178982. eCollection 2017. 28604798
A multilevel-ROI-features-based machine learning method for detection of morphometric biomarkers in Parkinson's disease. Peng B; Wang S; Zhou Z; Liu Y; Tong B; Zhang T; Dai Y; Neurosci. Lett. 2017 Jun;651():88-94 28435046
Portable objective assessment of upper extremity motor function in Parkinson's disease. Chahine LM; Uribe L; Hogarth P; McNames J; Siderowf A; Marek K; Jennings D; Parkinsonism Relat. Disord. 2017 Jul;(): 28747279
Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB; Brain 2017 Jul;140(7):1959-1976 28549077
Tau/?-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC; Mov. Disord. 2017 Jul;32(7):1066-1073 28548309
Evaluating the Performance of the Montreal Cognitive Assessment in early stage Parkinson's disease. Kletzel, S.L., Hernandez, J.M., Miskiel, E.F., Mallinson, T., Pape, T.L. Parkinsonism Relat Disord. 2017 Jan 28. pii: S1353-8020(17)30029-9. doi: 10.1016/j.parkreldis.2017.01.012. 28189463
Clinical Variables and Biomarkers in Prediction of Cognitive Impairment in Patients With Newly Diagnosed Parkinson's Disease: a Cohort Study Schrag A, Weintraub D, Siddiqui U, Jichi F, Schott J Lancet Neurol. 2017 Jan;16(1):66-75. CSF 27866858
Does apolipoprotein A1 predict microstructural changes in subgenual cingulum in early Parkinson? Rahmani F; Aarabi MH; J. Neurol. 2017 Feb;(): 28168521
Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity. Webb J; Willette AA; Neurobiol. Aging 2017 Feb;50():39-46 27871051
Improved prediction of outcome in Parkinson's disease using radiomics analysis of longitudinal DAT SPECT images. Rahmim A, Huang P, Shenkov N, Fotouhi S, Davoodi-Bojd E, Lu L, Mari Z, Soltanian-Zadeh H, Sossi V. Neuroimage Clin. 2017 Aug 26;16:539-544. doi: 10.1016/j.nicl.2017.08.021. eCollection 2017. DAT SPECT; Longitudinal; Outcome prediction; Parkinson's disease; Radiomics; Textural features 29868437
Latent Cognitive Phenotypes in De Novo Parkinson's Disease: A Person-Centered Approach. LaBelle DR; Walsh RR; Banks SJ; J Int Neuropsychol Soc 2017 Aug;23(7):551-563 28651678
Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. Ffytche DH, Pereira JB, Ballard C1, Chaudhuri KR, Weintraub D, Aarsland D. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):325-331. doi: 10.1136/jnnp-2016-314832. 28315846
Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease Picillo M, Santangelo G, Erro R, Cozzolino A, Amboni M, Vitale C, Barone P, Pellecchia MT. Parkinsonism Relat Disord. 2017 Apr;37:106-110 28214265
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson?s Disease Clinical Trials: A Disease Progression Modeling Analysis Daniela J. Conrado1,?, Timothy Nicholas2, Kuenhi Tsai3, Sreeraj Macha3, Vikram Sinha3, Julie Stone3, Brian Corrigan2, Massimo Bani4, Pierandrea Muglia1, Ian A. Watson5, Volker D. Kern1, Elena Sheveleva1,6, Kenneth Marek7, Diane T. Stephenson1 and Klaus Romero1 on behalf of the Critical Path for Parkinson?s (CPP) Parkinson?s Disease Modeling and Simulation Working Group ClinTranslSci. 2017 Jul;00:1?8 28749580
A test-retest study on Parkinson's PPMI dataset yields statistically significant white matter fascicles. Cousineau M; Jodoin PM; Morency FC; Rozanski V; Grand\'Maison M; Bedell BJ; Descoteaux M; Neuroimage Clin 2017 ;16():222-233 28794981
Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease. Santiago JA, Littlefield AM, Potashkin JA. Sci Rep. 2016 Sep 29;6:34579. doi: 10.1038/srep34579. transcriptomics, biomarker 27680512
T2-Imaging Changes in the Nigrosome-1 Relate to Clinical Measures of Parkinson's Disease. Fu KA, Nathan R, Dinov ID, Li J, Toga AW. Front Neurol. 2016 Oct 20;7:174 MRI; Parkinson’s disease; movement disorders; nigrosome-1 27812347
Joint feature-sample selection and robust diagnosis of Parkinson's disease from MRI data. Adeli E; Shi F; An L; Wee CY; Wu G; Wang T; Shen D; Neuroimage 2016 Nov;141():206-19 27296013
Cerebrospinal Fluid Amyloid ?1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease. Kang JH J Mov Disord. 2016 May;9(2):89-96. PMC4886208
Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder Chahine LM, Xie SX, Simuni T, Tran B, Postuma R, Amara A, Oertel WH, Iranzo A, Scordia C, Fullard M, Linder C, Purri R, Darin A, Rennert L, Videnovic A, Del Riva P, Weintraub D. Parkinsonism Relat Disord. 2016 Mar 12. pii: S1353-8020(16)30060-8. doi: 10.1016/j.parkreldis.2016.03.006. [Epub ahead of print] Cognition; Dementia; REM sleep behavior disorder 27010070
High-Accuracy Detection of Early Parkinson's Disease through Multimodal Features and Machine Learning Prashanth R, Dutta Roy S, Mandal PK, Ghosh S. Int J Med Inform. 2016 Jun;90:13-21. doi: 10.1016/j.ijmedinf.2016.03.001. Epub 2016 Mar 5. Computer-aided diagnosis; Parkinson?s disease; cerebrospinal fluid markers; dopaminergic imaging; non-motor features; pattern classification 27103193
High Accuracy Classification of Parkinson's Disease through Shape Analysis and Surface Fitting in 123I-Ioflupane SPECT Imaging Prashanth R, Dutta Roy S, Mandal PK, Ghosh S. IEEE J Biomed Health Inform. 2016 Mar 29. [Epub ahead of print] Scans Without Evidence of Dopaminergic Deficit (SWEDD), Single Photon Emission Computed Tomography (SPECT), Striatal Binding Ratio (SBR)-based features, Support Vector Machine (SVM) classifier 27101625
Structural Brain Alterations Associated with Rapid Eye Movement Sleep Behavior Disorder in Parkinson?s Disease Soufiane Boucetta, Ali Salimi, Mahsa Dadar, Barbara E. Jones, D. Louis Collins, and Thien Thanh Dang-Vua Sci Rep. 2016 Jun: 26782 27245317
Predictors of time to initiation of symptomatic therapy in early Parkinson's disease. Simuni T; Long JD; Caspell-Garcia C; Coffey CS; Lasch S; Tanner CM; Jennings D; Kieburtz KD; Marek K; PPMI Investigators; Ann Clin Transl Neurol 2016 Jul;3(7):482-94 27386498
Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. Davis AA, Andruska KM, Benitez BA, Racette BA, Perlmutter JS, Cruchaga C. Neurobiol Aging. 2016 Jan;37:209.e1-7. doi: 10.1016/j.neurobiolaging.2015.09.014. Epub 2015 Sep 30. Age at onset; GBA; MAPT; Motor progression; Parkinson disease; SNCA 26601739
Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants Nuytemans K, Maldonado L, Ali A, John-Williams K, Beecham GW, Martin E, Scott WK, Vance JM. Neurol Genet. 2016 Jan 14;2(1):e44. doi: 10.1212/NXG.0000000000000044. eCollection 2016. ATP-binding cassette transporter A7 (ABCA7), whole-exome sequencing, 27066581
Neural substrates of excessive daytime sleepiness in early drug naïve Parkinson's disease: A resting state functional MRI study. Wen MC; Ng SY; Heng HS; Chao YX; Chan LL; Tan EK; Tan LC Parkinsonism Relat Disord. 2016 Jan 12. pii: S1353-8020(16)30012-8. 26810915
Age at onset and Parkinson disease phenotype Pagano G, Ferrara N, Brooks DJ, Pavese N. 2016 Feb 10. pii: 10.1212/WNL.0000000000002461. [Epub ahead of print] biomarkers, DaTSCAN imaging, age of onset 26865518
COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P; COPPADIS Study Group; BMC Neurol 2016 Feb;16():26 26911448
Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations. Dinov ID, Heavner B, Tang M, Glusman G, Chard K, Darcy M, Madduri R, Pa J, Spino C, Kesselman C, Foster I, Deutsch EW, Price ND, Van Horn JD, Ames J, Clark K, Hood L, Hampstead BM, Dauer W, Toga AW. PLoS One. 2016 Aug 5;11(8):e0157077. doi: 10.1371/journal.pone.0157077. eCollection 2016. 27494614
A Novel GA-ELM approach for Parkinson's disease detection using Brain Structural T1-weighted MRI Data Gunjan Pahuja, T.N. Nagabhushan IEEE Brain Structural, T1-weighted MRI Data, Parkinson's, detection
Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease Kraemmer J, Smith K, Weintraub D, Guillemot V, Nalls MA, Cormier-Dequaire F, Moszer I, Brice A, Singleton AB, Corvol JC. J Neurol Neurosurg Psychiatry. 2016 Apr 13. pii: jnnp-2015-312848. doi: 10.1136/jnnp-2015-312848. [Epub ahead of print] Impulse control disorders, dopamine replacement therapy, ICD heritability 27076492
White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration. Kandel BM Avants BB, Gee JC, McMillan CT, Erus G, Doshi J, Davatzikos C, Wolk DA. Alzheimers Dement (Amst). 2016 Apr 7;4:18-27. doi: 10.1016/j.dadm.2016.03.001. eCollection 2016. Aging; Alzheimer's disease; Amyloid; Leukoaraiosis; MRI; PET; Preclinical Alzheimer's disease; White matter 27489875
Olfactory impairment predicts cognitive decline in early Parkinson's disease. Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF; Parkinsonism Relat. Disord. 2016 Apr;25():45-51 26923521
CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report. Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y; PLoS ONE 2016 ;11(10):e0164762 27764160
Progression of Regional Microstructural Degeneration in Parkinson's Disease: A Multicenter Diffusion Tensor Imaging Study. Zhang Y; Wu IW; Tosun D; Foster E; Schuff N; Parkinson?s Progression Markers Initiative; PLoS ONE 2016 ;11(10):e0165540 27798653
Statistical Approach towards Parkinson’s Disease Progression Pahuja G, Nagabhushan TN, Journal of Parkinson\'s Dis Alzheimer Dis 3(2): 6 Statistical, Parkinson’s, Progression
Network structure of brain atrophy in de novo Parkinson's disease Zeighami Y, Ulla M, Iturria-Medina Y, Dadar M, Zhang Y, Larcher KM, Fonov V, Evans AC, Collins DL, Dagher A. Elife. 2015 Sep 7;4. doi: 10.7554/eLife.08440 MRI; basal ganglia; deformation-based morphometry; human; independent component analysis; neuroscience; substantia nigra 26344547
CSF ?-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease. Terrelonge M; Marder KS; Weintraub D; Alcalay RN; J. Mol. Neurosci. 2015 Sep. doi 10.1007/s12031-015-0647-x [Epub ahead of print] CSF beta-amyloid 1-42; cognitive impairment 26330275
Graph-theory-based spectral feature selection for computer aided diagnosis of Parkinson's disease using T1-weighted MRI Rana B; Juneja A; Saxena M; Gudwani S; Kumaran SS; Behari M; Agrawal RK Int J Imag Syst Tech. 2015 Sep;25(3):245-55. computer-aided diagnosis; magnetic resonance imaging; spectral feature selection
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Nalls MA; McLean CY; Rick J; Eberly S; Hutten SJ; Gwinn K; Sutherland M; Martinez M; Heutink P; Williams NM; Hardy J; Gasser T; Brice A; Price TR; Nicolas A; Keller MF; Molony C; Gibbs JR; Chen-Plotkin A; Suh E; Letson C; Fiandaca MS; Mapstone M; Federoff HJ; Noyce AJ; Morris H; Van Deerlin VM; Weintraub D; Zabetian C; Hernandez DG; Lesage S; Mullins M; Conley ED; Northover CA; Frasier M; Marek K; Day-Williams AG; Stone DJ; Ioannidis JP; Singleton AB; Parkinson\'s Disease Biomarkers Program and Parkinson\'s Progression Marker Initiative investigators; Lancet Neurol 2015 Oct;14(10):1002-9 26271532
Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients. Santiago JA, Potashkin JA PLoS One. 2015 Nov 13;10(11):e0142582. doi: 10.1371/journal.pone.0142582. eCollection 2015. 26566043
Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease Smith KM, Xie SX, Weintraub D J Neurol Neurosurg Psychiatry. 2015 Nov 3. pii: jnnp-2015-311827. doi: 10.1136/jnnp-2015-311827 Impulse control disorder; dopamine transported imaging; DaT 26534930
Computer-Aided Diagnosis of Parkinson's Disease Using Enhanced Probabilistic Neural Network Hirschauer TJ, Adeli H, Buford JA. J Med Syst. 2015 Nov;39(11):179. doi: 10.1007/s10916-015-0353-9. Epub 2015 Sep 29. Computer-aided diagnosis; Enhanced probabilistic neural networks; Parkinson?s disease 26420585
Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease Stephenson D, Hu MT, Romero K, Breen K, Burn D, Ben-Shlomo Y, Bhattaram A, Isaac M, Venuto C, Kubota K, Little MA, Friend S, Lovestone S, Morris HR, Grosset D, Sutherland M, Gallacher J, Williams-Gray C, Bain LJ, Avilés E, Marek K, Toga AW, Stark Y, Forrest Gordon M, Ford S. J Parkinsons Dis. 2015;5(3):581-94. doi: 10.3233/JPD-150570 Data standards; collaboration; data integration; privacy; quantitative disease progression; regulatory science 26406139
Nonmotor Symptoms in Subjects Without Evidence of Dopaminergic Deficits. Sprenger FS; Seppi K; Djamshidian A; Reiter E; Nocker M; Mair K; Göbel G; Poewe W Mov Disord. 2015 Mar 15. doi: 10.1002/mds.26204. [Epub ahead of print] SWEDDs; nonmotor symptoms; orthostatic hypotension; autonomic dysfunction; hyposmia 25772612
Morphological alterations in the caudate, putamen, pallidum, and thalamus in Parkinson's disease. Garg A; Appel-Cresswell S; Popuri K; McKeown MJ; Beg MF Front Neurosci. 2015 Mar 31;9:101. doi: 10.3389/fnins.2015.00101. eCollection 2015. LDDMM; MRI; prediction; shape analysis; surface displacement; disease severity 25873854
Planning for selective amygdalohippocampectomy involving less neuronal fiber damage based on brain connectivity using tractography. Lee SH, Kim M, Park H. Neural Regen Res. 2015 Jul;10(7):1107-12. doi: 10.4103/1673-5374.160104. betweenness centrality; connectivity; diffusion tensor imaging; epilepsy; magnetic resonance imaging; nerve regeneration; network analysis; neural regeneration; neuronal fibers; selective amygdalohippocampectomy; temporal lobe surgery; tractography 26330834
Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Qamhawi Z; Towey D; Shah B; Pagano G; Seibyl J; Marek K; Borghammer P; Brooks DJ; Pavese N Brain. 2015 Jul 23. pii: awv215. [Epub ahead of print] serotonin; SPECT; tremor; non-motor 26209314
Plasma Apolipoprotein A1 Associates With Age at Onset and Motor Severity in Early Parkinson's Disease Patients. Swanson CR; Berlyand Y; Xie SX; Alcalay RN; Chahine LM,;Chen-Plotkin AS Mov Disord. 2015 Jul 24. doi: 10.1002/mds.26290. [Epub ahead of print] apolipoprotein A1; biomarker 26207725
Longitudinal Study of Gray Matter Changes in Parkinson Disease Jia X, Liang P, Li Y, Shi L, Wang D, Li K. AJNR Am J Neuroradiol. 2015 Dec;36(12):2219-26. doi: 10.3174/ajnr.A4447. Epub 2015 Sep 10 structural MR imaging, voxel-based morphometry analysis, structural MR imaging 26359153
Ipsilateral deficits of dopaminergic neurotransmission in Parkinson's disease Kaasinen V. Ann Clin Transl Neurol. 2015 Dec 5;3(1):21-6. doi: 10.1002/acn3.268. eCollection 2016 Jan. 26783547
Unsupervised learning based feature extraction for differential diagnosis of neurodegenerative diseases: A case study on early-stage diagnosis of Parkinson disease. Singh G; Samavedham L; J. Neurosci. Methods 2015 Dec;256():30-40 26304693
Patterns of Motor and Non-Motor Features in Medication-Naïve Parkinsonism Jain S; Park SY; Comer D Neuroepidemiolgoy. 2015 Aug;45(1):59-69. non-motor 26227734
Genome-wide variant by serum urate interaction in Parkinson's disease. Nazeri A; Roostaei T; Sadaghiani S; Chakravarty MM; Eberly S; Lang AE; Voineskos AN Ann Neurol. 2015 Aug 18. doi: 10.1002/ana.24504. [Epub ahead of print] 26284320
Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease. Zhang Y; Wu IW; Buckley S; Coffey CS; Foster E; Mendick S; Seibyl J; Schuff N Mov Disord. 2015 Apr 29. doi: 10.1002/mds.26251. [Epub ahead of print] MRI; diffusion tensor imaging; DTI; diffusion tensor tractography; nigrostriatal pathway 25920732
Computer-aided diagnosis of Parkinson's disease based on [(123)I]FP-CIT SPECT binding potential images, using the voxels-as-features approach and support vector machines. Oliveira FP; Castelo-Branco M J Neural Eng. 2015 Apr;12(2):026008. doi: 10.1088/1741-2560/12/2/026008. Epub 2015 Feb 24. DaTSCAN; binding potential; classification; automated image analysis; SPECT 25710187
Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease Liu R; Umbach DM; Peddada SD; Xu Z; Tröster AI; Huang X; Chen H Neurology. 2015 May 26;84(21):2107-15. doi: 10.1212/WNL.0000000000001609. Epub 2015 Apr 29. nonmotor symptoms; olfaction; cognition; anxiety; autonomic function; sleep 25925983
Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Pereira JB; Svenningsson P; Weintraub D; Brønnick K; Lebedev A; Westman E; Aarsland D; Neurology. 2014 Jun 3;82(22):2017-25. doi: 10.1212/WNL.0000000000000483. Epub 2014 May 7. cortical thickness; thinning; mild cognitive impairment; MCI; atrophy; 24808018
Automatic classification and prediction models for early Parkinson?s disease diagnosis from SPECT imaging Prashanth R; Roy SD; Mandal PK; Ghoshd S Expert Syst Appl. 2014 June;41(7): 3333-3342 [Epub ahead of print] early diagnosis; SPECT imaging; single photon emission computed tomography; DaTSCAN; striatal binding ratio; SBR; support vector machine; SVM 23152757
REM Sleep Behavior and Motor Findings in Parkinson's Disease: A Cross-sectional Analysis Mahajan A; Rosenthal LS; Gamaldo C; Salas RE; Pontone GM; McCoy A; Umeh C; Mari Z Tremor Other Hyperkinet Mov (N Y). 2014 Jun 23;4:245. doi: 10.7916/D84B2ZDF. eCollection 2014. Movement Disorders Society-United Parkinson's Disease Rating Scale; motor findings; rapid eye movement sleep; RBD; MDS UPDRS-3; 25009765
Teaching Video NeuroImages: Spasmodic dysphonia preceding idiopathic parkinsonism. Hannah-Shmouni F; Matiello M; Russell DS; Hasbani MJ Neurology 2014 Feb;82(6):e55. spasmodic dysphonia; idiopathic parkinsonism; DaTscan; phonatory breaks; rest tremor 24514016
What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic? Kim D; Paik JH; Shin DW; Kim HS; Park CS; Kang JH Exp Neurobiol. 2014 Dec;23(4):352-64. doi: 10.5607/en.2014.23.4.352. Epub 2014 Dec 12. biomarker; cerebrospinal fluid; alpha-synuclein 25548535
Course of psychiatric symptoms and global cognition in early Parkinson disease de la Riva P; Smith K; Xie SX; Weintraub D Neurology. 2014 Sep 16;83(12):1096-103. doi: 10.1212/WNL.0000000000000801. Epub 2014 Aug 15. cognition; psychiatric symptoms; DRT; dopamine replacement therapy; neuropsychiatric symptoms; NPS 25128183
Parkinson's disease detection using olfactory loss and REM sleep disorder features Prashanth R; Roy SD; Mandal PK; Ghosh S Conf Proc IEEE Eng Med Biol Soc. 2014 Aug;2014:5764-7. doi: 10.1109/EMBC.2014.6944937. olfactory loss; sleep disorders; University of Pennsylvania Smell Identification Test; UPSIT; Rapid eye movement sleep Behavior Disorder Screening Questionnaire; RBDSQ; Support Vector Machine; SVM 25571305
Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. Lebedev AV; Westman E; Simmons A; Lebedeva A; Siepel FJ; Pereira JB; Aarsland D; Front Syst Neurosci. 2014 Apr;8:45. SPECT; cognition; dopamine; graph theory; modularity; nodal strength; resting state fMRI 24765065
Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease. Siepel FJ; Brønnick KS; Booij J; Ravina BM; Lebedev AV; Pereira JB; Grüner R; Aarsland D Mov Disord. 2014 Dec;29(14):1802-8. doi: 10.1002/mds.26051. Epub 2014 Oct 4. SPECT; [123I]FP-CIT; cognitive impairment; dopamine transporter; early cognitive decline 25284687
Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Goldman JG; Stebbins GT; Leung V; Tilley BC; Goetz CG Parkinsonism Relat Disord. 2014 Nov;20(11):1135-9. doi: 10.1016/j.parkreldis.2014.08.001. Epub 2014 Aug 13. cognitive impairment; daytime sleepiness; fatigue; Movement Disorder Society-Unified Parkinson's Disease Rating Scale; MDS-UPDRS; night-time sleep problems 25150770
CSF a-synuclein improves diagnostic and prognostic performance of CSF tau and AB in Alzheimers disease Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J Acta Neuropathol. 2013 Nov;126(5):683-97. Alzheimer?s disease; dementia with Lewy body; Cerebrospinal fluid; amyloid beta; tau; alpha-synuclein 23812319
Shape features as biomarkers in early Parkinson's disease Prashanth R; Roy SD; Ghosh S; Mandal PK Neural Engin. IEEE/EMBS Conf. 2013 Nov;doi: 10.1109/NER.2013.6695985:517,520 dopaminergic imaging; Single Photon Emission Computerized Tomography; SPECT; SWEDD; [123I]FP-CIT; biomarkers 27035571
Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease. Dolatshahi M, Pourmirbabaei S, Kamalian A, Ashraf-Ganjouei A, Yaseri M, Aarabi MH. Front Neurol. 2018 Jul 11;9:560. doi: 10.3389/fneur.2018.00560. eCollection 2018. Cerebrospinal fluid (CSF); Longitudinal; Parkinson's disease; alpha-synuclein; beta-amyloid; tau 30050494
Application of Texture Analysis to DAT SPEC Imaging: Relationship to Clinical Assessments Arman Rahmim, Yousef Salimpour, Saurabh Jain, Stephan Blinder, Ivan Klyuzhin, Gwenn Smith, Zoltan Mari, Vesna Sossi Neuroimage Clin. 2016 Feb 23;12:e1-e9 DAT SPEC, Progression 27995072
Aberrant Cerebral Network Topology and Mild Cognitive Impairment in Early Parkinson's Disease Christine R. Swanson, Yosef Berlyand, Sharon X. Xie, Lama A. Chahine, and Alice S. Chen-Plotkin Hum Brain Mapp. 2015 Aug;36(8):2980-95. Cerebral Network, Cognitive Impairment 25950288
Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort. Holden SK; Finseth T; Sillau SH; Berman BD; Mov Disord Clin Pract ;5(1):47-53 29662921